Search
Nonoxynol-9
go.drugbank.com/drugs/DB06804ApprovedWithdrawnN-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams and condom lubricants. … Nonoxynol-9 (N-9) is a typical surfactant used as a vaginal spermicide. Spermicides are locally acting non-hormonal contraceptives.
Categories: Compounds used in a research, industrial, or household settingFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalAlso known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade. … As a result, the active transglutaminase from subunit A cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to fibrinolysis of the fibrin clot.
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Myrrh
go.drugbank.com/drugs/DB11605ApprovedInvestigationalExtractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation. … [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.
Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamideAnisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedIts use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … action on the bile ducts and gallbladder.
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.
Oxitriptan
go.drugbank.com/drugs/DB02959ApprovedInvestigationalNutraceuticalWithdrawnthe United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication … 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalIt was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.